

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057300 A1

- (51) International Patent Classification⁷: **C07K 14/00**, C12P 19/34
- (21) International Application Number: PCT/US01/50777
- (22) International Filing Date:
19 December 2001 (19.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/257,002 21 December 2000 (21.12.2000) US
- (71) Applicants (*for all designated States except US*):
SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). **LIGAND PHARMACEUTICALS** [US/US]; 10275 Science Center Drive, San Diego, CA 92121 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **DELORME, Evelyn, O.** [US/US]; 10275 Science Center Drive, San Diego, CA 92121 (US). **DUFFY, Kevin, J.** [GB/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **LAMB, Peter, I.** [GB/US]; 814 Mandana Boulevard, Oakland, CA 94610 (US). **LUENGO, Juan, I.** [ES/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **TIAN, Shin-Shay, C.** [US/US]; 12415 Mona Lisa Street, San Diego, CA 92130 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS

(57) Abstract: Invented is a regulated activation of cell-membrane receptors by small molecule agents. Also invented is a method to render a cell-membrane receptor responsive to the activation by small molecule compounds by specific single point mutations in the transmembrane region.



WO 02/057300 A1

REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL- CHELATING AGONISTS

FIELD OF THE INVENTION

5 This invention relates to a method to regulate the activation of cell-surface
receptors with small molecule agonists by engineering specific point mutations in the
transmembrane domains of the receptors. More specifically, the invention describes a
method to promote the oligomerization of mutated multimeric receptors using compounds
that can chelate metal ions such as zinc (II). Transfection of these modified receptors into
10 host cells provides numerous therapeutic opportunities in gene therapy and other
applications related to inducible signal transduction in transduced cells.

BACKGROUND OF THE INVENTION

Dimerization and oligomerization of cell-surface receptors is a key biological
15 process by which extracellular molecules can regulate diverse biological responses within
the cell such as proliferation, differentiation or apoptosis. This signaling mechanism is
utilized by many soluble proteins, such as cytokines, hormones and growth factors, which
exert their biological functions through the interaction and subsequent aggregation of
specific cell-surface receptors. (Arai, K.-I. et al. *Annu. Rev. Biochem.* 1990, 59, 783;
20 Bazan, J. F. *Proc. Natl. Acad. Sci. U.S.A.* 1990, 87, 6934; Ullrich A. and Schlessinger, J.
Cell, 1990, 61, 203-212; Young, P. R. "Protein hormones and their receptors", *Curr. Opin.*
Biotech. 1992, 3, 408-421; Heldin, C. H., "Dimerization of cell surface receptors in signal
transduction" *Cell*, 1995, 80, 213-223). These receptors are comprised of three distinct
domains: an extracellular ligand-binding domain, a transmembrane domain and a
25 cytoplasmic domain, which is responsible for signal transduction within the cell. Receptor
dimerization is the first step in a signaling cascade that is mediated by receptor-associated
tyrosine kinases. These kinases are activated by autophosphorylation and, in turn,
phosphorylate a number of other intracellular targets, such as the cytoplasmic domain of
the receptor, adapter proteins and STATs (signal transducers and activators of
30 transcription). The tyrosine-phosphorylated proteins propagate the signaling cascade by
acting as binding sites for other intracellular proteins, a process that ultimately results in the
initiation of transcription of the specific responsive genes. Some receptors, such as those
for thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) erythropoietin
(EPO) and growth hormone consist of a single polypeptide subunit. Others, such as
35 receptors for interleukin-2 (IL-2), IL-3, IL-4, IL-5 and IL-6, consist of two or three
different chains each performing more specialized functions, such as ligand binding and
signal transduction. Although the mechanism of receptor activation varies for specific

receptor-ligand pairs, a common feature of many single-transmembrane receptors appears to be their aggregation on the cell membrane in response to binding of their specific ligands. This aggregation event can be in the form of homodimerization, in the case of receptors with a single subunit, or heterodimerization, in the case of receptors with different subunits.

Recently, technology has been developed that allows the dimerization of chimeric cell-membrane receptors by dimeric forms of small molecule ligands derived from FK-506 or cyclosporin A (reviewed in Schreiber, *Bioorg. Med. Chem.* 1998, 6, 1127). In this work FK-1012, a lipid-soluble dimeric form of FK-506, is used to dimerize chimeric protein consisting of a cell-membrane receptor signaling domain fused to an FKBP12 domain. The ability of FK-1012 to homodimerize this fusion protein is based on the strong affinity between FK-506, a natural macrocyclic product, and FKBP12, an intracellular cytoplasmic protein present in all cells (Bierer et al. *PNAS*, 1990, 87, 9231). This methodology has been applied to the intracellular domains of a number of trans-membrane receptors, such as the zeta chain of the T-cell receptor (Spencer et al., *Science* 1993, 262, 1019; Pruschy et al. *Chem. Biol.* 1994, 1, 164), Fas receptor (Belshaw et al. *Chem. Biol.* 1996, 3, 731; Spencer et al., *Current Biol* 1996, 6, 839), TGF-beta receptor (Spencer et al., *Current Biol* 1998, 8, 761), EPO receptor (Blau et al. *PNAS*, 1997 94, 3076), *c-kit* receptor (Jin et al. *Blood* 1998, 91, 890). Full reports describing the applications of this technology to the regulation of transcription have recently appeared (US 6140120, US 6063625, US 6054436, US 6046047, US 6043082, US 6011018, US 5994313, US 5871753, US 5869337, US 5834266, US 5830462).

All of the reports listed above involve the construction of chimeric transmembrane proteins consisting of the fusion between a cytoplasmic domain, which contains the signal transduction signal, and a ligand-binding domain, either derived from FKBP12 or cyclophilin. None of the reports suggest a method whereby a transmembrane receptor can be made responsive to the action of small-molecule activators through specific point mutations in their transmembrane domain.

As disclosed herein it has unexpectedly been discovered that by simple mutation of two specific residues within their transmembrane domain, cell-membrane receptors can be specifically activated by small-molecule metal-chelated ligands, such as those described in PCT/US98/23049, published as International Application No. WO 99/22732 on May 14, 1999.

SUMMARY OF THE INVENTION

Accordingly, one aspect of the present invention is a method for activating dimeric or oligomeric cell-surface receptors which comprises mutating a specific amino acid within

the transmembrane domain of the receptor to histidine and thereafter contacting the mutated cell-surface receptor with a metal-chelating receptor agonist.

Another aspect of the present invention is a method for activating dimeric or oligomeric cell-surface receptors which comprises mutating two specific amino acids, preferably three residues apart, within the transmembrane domain of the receptor, to threonine and histidine and thereafter contacting the mutated dimeric cell-surface receptor with a metal-chelating receptor agonist.

Another aspect of the invention relates to dimeric or oligomeric cell-surface receptors containing one point mutation of a specific amino acid within the transmembrane domain of the receptor to histidine.

Another aspect of the invention relates dimeric or oligomeric cell-surface receptors containing two point mutations of specific amino acids, preferably three residues apart, within the transmembrane domain of the receptor to threonine and histidine.

Another aspect of the invention relates to a host cell having dimeric or oligomeric cell-surface receptors containing one point mutation of a specific amino acid within the transmembrane domain of the receptor to histidine.

Another aspect of the invention relates to a host cell having dimeric or oligomeric cell-surface receptors containing two point mutations of a specific amino acids, preferably three residues apart, within the transmembrane domain of the receptor to threonine and histidine.

DETAILED DESCRIPTION OF THE INVENTION

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as though fully set forth.

By the term "heteroatom(s)", as used herein is meant nitrogen, oxygen or sulfur, preferably nitrogen.

By the term "treating" and derivatives thereof as used herein, is meant prophylactic or therapeutic therapy.

By the term "organic molecule" and derivatives thereof as used herein, is meant the standard usage in the art to the ordinary organic chemist and as such excludes inorganic molecules and peptide molecules.

By the term "cell-membrane receptor" as used herein, is meant a protein macromolecule that spans the cell membrane and can transmit a signal from the extracellular media to the inside of the cell. Most natural cell-membrane receptors contain three regions: extracellular, transmembrane and intracellular domains. The extracellular domain serves as recognition site for specific ligands, the transmembrane domain acts as an anchor of the receptor to the cell membrane, and the intracellular domain typically contains

recognition sequences that transduce the external signal to the inside of the cells. Further cell-membrane receptors within this invention can be comprised of only two domains: the transmembrane domain, typically a region of about 18-30 aminoacids with an overall non-polar nature, and the intracellular domain, typically a region of 40-300 amino acids
 5 containing recognition sequences involved in signal initiation, such as the Box1, Box2 and tyrosine residues found in cytokine receptors (see Fukunaga et al., Cell, 1993, 74, 1079; Tanner et al, J. Biol. Chem. 1995, 270, 6523; Gurney et al., Proc Nat. Acad. Sci. USA 1995, 92, 5292).

All of the receptors within this invention have at least one point mutation.

10 By the term "metal-chelating receptor agonists", and derivatives thereof, as used herein means a small organic molecule having a molecular weight from about 100 to about 850, preferably having a molecular weight from about 200 to about 750, most preferably having a molecular weight from about 300 to about 650 and having from 1 to 4 metal binding motifs, preferably having one or two metal binding motifs. In one embodiment,
 15 metal chelation forms a symmetrical multimer, such as a dimer, of the receptor binding moiety.

By the term "metal binding motif", and derivatives thereof, as used herein means a continuation of atoms within a receptor binding moiety that have the following characteristics:

20 1) each continuation consist of 3 to 10 atoms, preferably 4 to 8 atoms, most preferably 4 or 5 atoms,

2) each continuation further consisting of two or more heteroatoms, preferably from 2 to 4 heteroatoms, most preferably 2 to 3 heteroatoms, preferably at least one of the heteroatoms is nitrogen, wherein the heteroatoms are separated from each other
 25 by one to four additional atoms selected from the group consisting of carbon, nitrogen, sulfur and oxygen, preferably carbon or nitrogen, preferably by 2 to 4 additional atoms, most preferably by 2 or 3 additional atoms, and

3) the configuration of heteroatoms within the metal binding motif allows for chelate coordination to a metal ion, such as a zinc (II), copper(II), nickel(II), iron(II), cobalt(II), manganese(II) ions, by providing for the formation of at least two coordinate bonds, preferably two or three coordinate bonds, simultaneously to a metal ion.
 30


Examples of metal binding motifs for use in the present invention include but are not limited to the following: -N-C-C-N-, -N-C=C-N-, -N-C-C=N-, -N=C-C=N-, -O-C-C-N-, -O-C=C-N-, -O-C-C=N-, -O=C-C=N-, -S-C-C-N-, -S-C=C-N-, -S-C-C=N-, -S=C-C=N-, -S-C-C-S-, -N=C-N-N-, -N-C-N-N-, -O=C-N-N-, -S=C-N-N-, -O-C-C=O-, -O-N-C=O-, -O=C-C=N-N-, -N=C-N-C=N-, -O=C-N-C=N-, -N=C-C-C=N-, -O-C=C-C=O-, -N-C-C-C-N-, -N-C-C=C-N-, -N=C-C=C-N-, -N=C-C=C-O-, -N-C-C=C-O-, -N=C-C=C-S-, -S=C-

C=C-S-, -O=C-N-C=N-, -N-N-C-C=N-, -N-N-C-N-N-, -N-C=N-C=N-, -N=C-N-C=N-C-C-N- and -N=C-N-C=N-C-C=N-. Further, the preferred metal binding motifs of the invention can be included as part of a combination. For example, the 8 atom zinc binding motif, -N=C-N-C=N-C-C=N-, in essentially an overlap of a 5 atom metal binding motif (that is -N=C-N-C=N-) and a 4 atom metal binding motif (that is -N-C-C=N-).

Preferred receptor binding moieties of the present invention comprise one or more of the following functional groups, preferably one or two of the following functional groups: 4-hydrazono-5-pyrazolones, 2-hydrazinophenols, 1-(2'-hydroxyphenyl)-thiosemicarbazones, 2-aryl-9-hydroxy-1H-naphtho[1,2-d]imidazoles, 2-guanidinobenzimidazoles, 2-guanidinobenzoxazoles, 2-guanidionbenzothiazole, 2-mercaptomethylpyridines, acylacetones, acylhydrazines, 2-aminoethanethiols, 2-(imidazol-4-yl)ethylamines, 2-(imidazol-2-yl)ethylamines, 2-(imidazol-4-yl)ethylamines, 2-(imidazol-2-yl)ethylamines, 2-picolylamine, 8-hydroxyquinolines, 8-aminoquinolines, 8-mercaptoquinolines, ethylenediamines, pyridine-2-carboxaldehydes, 2,2'-bipyridyls, 2-thiobenzaldehydes, 2-hydroxybenzaldehydes and 3'-{N'-[1-aryl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acids.

The above functional groups will generally form part of a larger molecule and may be further substituted in the formation of a receptor binding moiety. Preferred substituents for optional use on the above functional groups consist of one or more groups selected from the following: alkyl, aryl, hydroxy, alkoxy, acyloxy, carbamoyl, amino, N-acylamino, ketone, halogen, cyano, thio, carboxy and carboxamido.

International Application No. PCT/US99/30371, published as WO 00/35446 on June 22, 2000, discloses that the TPO receptor can be activated by small molecule ligands of Formula (I). To evaluate the role of the TPO receptor (Vigon et al. Proc. Natl. Acad. Sci. USA 1992, 89, 5640-5644) in compound action, we tested whether a cell line that did not respond to compounds could be rendered sensitive to compounds by expression of human TPO receptor. When transfected with a STAT-responsive luciferase reporter, cells from the human hepatoma cell line HepG2 (Aden et al. Nature, 1979, 282, 615) do not respond to TPO or compounds of Formula (I), but when cotransfected with a human TPO receptor expression vector and a reporter, the cells show a large increase in luciferase expression upon TPO treatment. Further, the cells also become responsive to the small-molecule agonists of Formula (I), with an activity pattern that was dependent on expression of the TPO receptor, indicating that the site of action of these compounds is the receptor itself.



To further investigate the activity of compounds of Formula (I), cDNA clones for cynomolgous monkey TPO receptor were isolated and sequenced. Surprisingly, there was

5 no activity detected by the compounds of Formula (I) against the cyno TPO receptor, despite the high degree of amino acid identity in its sequence when compared to that of the human receptor (96.5%). It was clear from these experiments that the compounds of

Formula I show strict specificity for the human TPO receptor, a finding also confirmed by STAT activation assays of platelets from human and cyno origin. In order to examine the

10 region of the TPO receptor required for compound activity, a series of human/cyno TPO-R chimeric receptors were transfected into HepG2 cells and tested for their response to compounds of Formula (I). Results from these studies showed that the compounds were active on chimeras that have the human transmembrane domain, and not on those derived from a cyno transmembrane domain. Comparison of the transmembrane sequences of


15 human and cyno TPO receptors reveals a single amino acid difference, histidine at the amino acid position 499 in the human receptor is changed to leucine in the cyno. To investigate the role of this specific transmembrane domain mutation on the activity of compounds of Formula (I), two point mutations were constructed: a) a H499L change into the human TPO receptor transmembrane domain, creating a receptor with human

20 extracellular and cytoplasmic domains and a cyno receptor transmembrane domain and b) a L499H change into the cyno receptor transmembrane domain creating a chimera with cyno extracellular and cytoplasmic domains and a human transmembrane domain. The H499L point mutation in the human TPO receptor rendered the receptor unresponsive to compounds of Formula (I), but had little effect on the response to TPO. Conversely, the

25 L499H mutation in the cyno TPO receptor allowed it to be activated by both TPO and the compounds with potencies and efficacies similar to those seen on wild type human receptor. This single amino acid difference in the transmembrane domain was found to be responsible for the species specificity of this series. In analogy to the cyno receptor, the murine TPO receptor also has a leucine at the position equivalent of human Leu499 in the transmembrane domain and, as expected, it is also unresponsive to the action of compounds


30 of Formula (I).

In another example of the invention, the murine G-CSFR was selected to test if the introduction of a His in the transmembrane region would render the receptor responsive to the action of compounds of Formula (I). As shown in Formula (II), the mGCSF-R (Fukunaga et al. Cell, 1990, 61, 341-350) does not contain a His in the transmembrane region and, consequently, was unresponsive to the effects of the compounds when transfected in into HepG2 cells.



However, as shown in Fig 1 when the transmembrane Cys610 was changed to a His, the resulting mGCSF-R mutant became responsive to the action of compounds of Formula (I). The double mutant G607T / C610H mG-CSFR also became responsive to the action of the compounds, and showed higher levels of sensitivity than the corresponding C610H single mutant. These studies indicate that introduction of a histidine residue in the transmembrane domain of single-pass cell-surface receptors renders them responsive to their activation by compounds of Formula (I). Further, this effect can be amplified by the concomitant introduction of a threonine, preferably, three amino acids upstream from the histidine. This effect is mediated by metal ions, as demonstrated by the fact that no activation took place in the presence of a metal chelating agent such as EDTA (see Fig 1).

The metal ion-dependence indicates the formation of a metal complex between compounds of Formula (I) and the receptor involving the His and Thr residues from the transmembrane domain. This complex, in turn, results in receptor activation by aggregation of receptor subunits on the surface of the cell.



(Fig 1)

5 In determining the efficacy and potency of the presently invented compounds as agonists of dimeric cell-surface receptors, a luciferase reporter gene assay configured in HepG2 cells was utilized (see Tian et al., Science 1998, 281, 257-259).

10 Without further elaboration, it is believed that one skilled in the art can, using the proceeding description, utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.

Experimental Details

15

Example 1

TPO-R Plasmid Constructs:

20 Human Tpo receptor (hMPL) was cloned from HEL 92.1.7 cells (ATCC, Rockville, MD) by PCR (forward primer: 5'-ACG AAG CTT AGC CAA GAT GTC TCC TTG CTG GCA T-3' and reverse primer: 5'-AGC CTC GAG TCA AGG CTG CTG CCA ATA GCT-3'). The cloned full-length cDNA was confirmed by DNA sequencing analysis, then subcloned into HindIII-XhoI digested pSSF vector. The cynomolgous Tpo-R (cMPL) was cloned from bone marrow cDNA using the human 5' and 3' terminal coding sequences.

The full-length cDNA was sequenced and subcloned into EcoRI digested pCDNA3.1 (+) vector (Invitrogen, San Diego, CA). Using the hMPL cDNA as a template, the BamHI-EcoRI fragment (nucleotides 787-1836) was replaced with the corresponding cynomolgous fragment to generate h/cMPL-1 and the SacI-EcoRI fragment (nucleotides 1400-1836) was replaced with the corresponding cynomolgous fragment to generate h/cMPL-2. The c/hMPL construct was generated by replacing the BamHI-XhoI fragment (nucleotides 787-1836) of the cMPL cDNA with the corresponding human fragment. Both the T(TMt)G and T(TMg)G constructs were cloned by bridge PCR. For T(TMt)G construct, chimeric primers (forward primer: 5'-CTG GGC CTG CTG CTG CTG AGC CCC AAC AGG AAG AAT-3' and reverse primer: 5'-ATT CTT CCT GTT GGG GCT CAG CAG CAG CAG GCC CAG-3') were used to join the extracellular domain and transmembrane domain of hMPL sequence with the cytoplasmic domain of the hG-CSF-R sequence. Chimeric PCR primers (forward primer: 5'-GCC ACC GAG ACC GCC TGG ATC ATC CTG GGC CTG TTC-3' and reverse primer: 5'-GAA CAG GCC CAG GAT GAT CCA GGC GGT CTC GGT GGC-3') were used to generate T(TMg)G construct by joining the extracellular domain of the hMPL sequence with the transmembrane domain and cytoplasmic domain of the hG-CSF-R sequence. The transmembrane domain single point mutants, hMPL(TM_c) and cMPL(TM_h) were generated by incorporating the desired mutations into PCR primers and the cloned products were confirmed by sequence analysis.

Example 2

HepG2 Transfection:

HepG2 cells were plated in 24-well plates in triplicates for overnight. The cells were then transfected with the indicated receptor construct, a GAS response element containing luciferase reporter, 8x118-TkLUC and STAT5b expression vector (a gift of Dr. James Ihle, Memphis, TN) by Superfect method (QIAGEN, Valencia, CA) as instructed by the manufacturer. After an overnight recovery, the transfected cells were treated with 0.1%DMSO, TPO or compound of Example 4 at the indicated concentrations for 4-5 hrs. The cells were then lysed and the level of luciferase expression was measured by a plate reader.

Example 3

GCSF-R Plasmid Constructs:

The transmembrane of the murine GCSF receptor was mutated with the following primers: 1) 5' CTA AAG CAT GTT GGC ACA AC 3'; 2) 5' CAT CTG ACC AGA AGG

AAG TC 3'; 3) 5' AAC ATT TTC CTG ACC ATA CTT CAC TTA 3'; 4) 5' TAA GTG AAG TAT GGT CAG GAA AAT GTT 3'. Primers 1 and 2 were designed to replace a cystein residue at position 610 with a histidine. A second mutation was performed with primers 3 and 4 to replace the glycine residue at position 607 with a threonine. The mutagenesis was performed according to the manufacturer's recommendations using QuikChange, a site-directed mutagenesis kit from Stratagene (cat. number 200518-5). The transmembrane region from eight clones from the His mutagenesis were sequenced using ThermoSequenase radiolabeled sequencing kit from USB (cat.79750). Seven clones were mutated. The receptor from one of the seven clones was sequenced in its entirety and proved to be correct. The gene was then transferred to a mammalian expression vector that had not gone through the mutagenesis protocol. The (His)GCSF-r was used to introduce the threonine mutation and produce the (His/Thr) double-mutant. Again 8 clones of the double mutant were screened for the mutation. All contained the His/Thr mutation. One of the double-mutants was fully sequenced and again transferred to an expression vector that had not gone through the mutagenesis procedure. The His and His/Thr GCSF-r plasmids were transfected overnight into HepG2 cells along with the 8x118Tk-Luc reporter using Lipofectamine Plus (GibcoBRL cat. 10964-013) following the manufacturer's protocol. The transfected cells were treated with compound or GCSF for 5 to 7hrs @ 37C in a humidified incubator. The cells were then lysed and assayed for luciferase production.

Example 4

Preparation of 3-Hydroxy-4-[(1-hydroxy-2-naphthalenyl)azo]-1-naphthalenesulfonic acid (compound 1)

The title compound is commercially available from Aldrich Chemical Company, Milwaukee, WI and used as provided. MS(ES) m/z 393 [M-H].

Example 5

Preparation of 3'-[N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino]-2'-hydroxybiphenyl-3-carboxylic acid (compound 2)

a) 2-Bromo-6-nitrophenol

2-Bromophenol (34.6 g, 0.2 mol) was added slowly to a cold (10°C) solution of sodium nitrate (30.5 g, 0.36 mol) in conc. sulfuric acid (42 g) and water (74 mL) and the resulting mixture was allowed to stir at room temperature for 2h. Water (210 mL) was

added and the resulting mixture was extracted with diethyl ether and the extract was dried (MgSO₄), filtered and concentrated. The residue was purified by flash chromatography (silica gel, 10% ethyl acetate/hexanes) to afford first the title compound (10.9 g; 25%) as a bright, yellow solid. ¹H NMR (300 MHz, CDCl₃) δ 11.10 (s, 1H), 8.13 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 7.9 Hz, 1H), 6.90 (t, J = 7.9 Hz, 1H).

b) 2-Bromo-6-nitroanisole

A mixture of the compound from Example 5a) (10.8 g; 0.0495 mol.), methyl iodide (3.4 mL; 0.00545 mol.) and potassium carbonate (8.2 g; 0.0592 mol.) in acetone (250 mL) was stirred and heated under reflux for 24h. The mixture was evaporated and the residue triturated with water to afford the title compound (8.7 g; 76%). mp 55-56°C. ¹H NMR (300 MHz, CDCl₃) δ 7.81-7.74 (m, 2H), 7.13 (t, J = 8.1 Hz, 1H), 4.02 (s, 3H); Anal. (C₇H₆NO₃Br) calcd: C, 36.24; H, 2.61; N, 6.04. found: C, 36.30; H, 2.59; N, 5.73.

c) 2'-Methoxy-3'-nitrobiphenyl-3-carboxylic acid

A solution of the compound from Example 5b) (4.06 g, 17.5 mmol.), 3-carboxyphenylboronic acid (3.04 g, 18.4 mmol.), 2M aq. sodium carbonate (17.5 mL; 35 mmol.) and tetrakis(triphenylphosphino) palladium(0) (875 mg) in 1,4-dioxane (105 mL) was stirred and heated under reflux under a nitrogen atmosphere for 24h.

The reaction mixture was cooled and evaporated and the residue treated with 6M aq. hydrochloric acid (150 mL). The grey precipitate was filtered and washed well with water then diethyl ether to afford the title compound (2.13g; 47%) as a tan powder. ¹H NMR (300 MHz, d₆-DMSO) δ 8.12 (s, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.94 (dd, J = 7.9 Hz, 1.5 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.76 (dd, J = 7.5, 1.5 Hz, 1H), 7.66 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 3.46 (s, 3H).

d) 2'-Hydroxy-3'-nitrobiphenyl-3-carboxylic acid

A solution of the compound from Example 5c) (2.13 g; 0.0077 mol.) in glacial acetic acid (25.0 mL) and 48% aq. hydrobromic acid (25.0 mL) was stirred and heated under reflux for 5h. The mixture was cooled and filtered to afford the title compound (1.57 g; 79%) as a tan powder. ¹H NMR (300 MHz, d₆-DMSO) δ 13.90 (s, 1H), 10.66 (s, 1H), 8.12 (t, J = 1.7 Hz, 1H), 8.07 (dd, J = 8.4, 1.7 Hz, 1H), 7.98 (dt, 7.8, 1.5 Hz, 1H), 7.79 (dt, J = 8.1, 1.7 Hz, 1H), 7.74 (dd, J = 7.5, 1.7 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 7.17 (dd, J = 8.4, 7.5 Hz, 1H).

e) 4-Amino-3'-hydroxybiphenyl-3-carboxylic acid, hydrochloride salt

A solution of the compound from Example 5d) (1.71 g, 6.6 mmol.) in ethanol (75.0 mL), water (50.0 mL) and 3M aqu. sodium hydroxide (2.1 mL, 6.8 mmol.) was hydrogenated over 10% palladium on carbon (210 mg) at room temperature and 50 psi for 2h. The reaction mixture was filtered, treated with 3M aqu. hydrochloric acid (25.0 mL) then evaporated and the residue triturated with a little water to afford the title compound (1.51 g; 100%) as a brown solid. ^1H NMR (300 MHz, d_6 -DMSO) δ 11.3-8.7 (br s, 4H), 8.08 (s, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.61 (t, J = 7.8 Hz, 1H), 7.34 (dd, J = 7.8, 1.4 Hz, 1H), 7.24 (dd, J = 7.8, 1.3 Hz, 1H), 7.04 (t, J = 7.8 Hz, 1H).

10 f) 1-(3,4-Dimethylphenyl)-3-methyl-3-pyrazolin-5-one

A solution of 3,4-dimethylphenylhydrazine hydrochloride (17.7 g; 0.1 mol.), ethyl acetoacetate (13.0 g; 0.1 mol.) and sodium acetate (8.2 g; 0.1 mol.) in glacial acetic acid (250 mL) was stirred and heated under reflux for 24h. The mixture was cooled and evaporated and the residue dissolved in diethyl ether (1L) and carefully washed with sat.

15 aqu. sodium hydrogen carbonate (5 x 200 mL). The ethereal layer was evaporated to afford the title compound (15.4 g; 76%). ^1H NMR (300 MHz, d_6 -DMSO) δ 11.30 (br s, 1H), 7.49 (d, J = 1.4 Hz, 1H), 7.43 (dd, J = 8.2 Hz, 1H), 7.14 (d, J = 8.2 Hz, 1H), 5.31 (s, 1H), 2.20 (s, 3H), 2.22 (s, 3H), 2.08 (s, 3H); MS(ES) m/z 203 [M+H].

20 g) 3'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid, hydrate

A suspension of the compound from Example 5e) (89.0 mg; 0.39 mmol.) in 1M aqu. hydrochloric acid (1.3 mL) was cooled to 5°C then treated dropwise with a solution of sodium nitrite (28.4 mg; 0.41 mmol.) in water (0.45 mL). The yellow mixture was stirred at 5°C for a further 10 min. then treated in one portion with the compound from Example 5f) (78.2 mg, 0.39 mmol.) followed by the portion-wise addition of sodium hydrogen carbonate (160 mg; 1.95 mmol.) and ethanol (1.8 mL) ensuring the final pH of the reaction mixture is approximately 7-8. The red solution was then stirred at room temperature for 24h. The mixture was filtered to give a red solid which was slurried in water (4.5L) and

30 then acidified with concentrated hydrochloric acid. Filtration afforded the title compound (0.055 g; 32%) as an orange solid. mp 228°C (dec.). ^1H NMR (300 MHz, d_6 -DMSO) δ 13.76 (s, 1H), 13.12 (s, 1H), 9.70 (s, 1H), 8.14 (s, 1H), 7.97 (dd, J = 7.7 Hz, 1H), 7.81 (dd, J = 7.7 Hz, 1H), 7.74-7.60 (m, 5H), 7.22-7.13 (m, 3H), 2.34 (s, 3H), 2.27 (s, 3H), 2.23 (s, 3H); Anal. ($\text{C}_{25}\text{H}_{22}\text{N}_4\text{O}_4 \cdot 1.0 \text{H}_2\text{O}$) calcd: C, 65.21; H, 5.25; N, 12.17. found: C, 65.60; H, 4.96; N, 12.04.

Example 6Preparation of 4-[[1-(3,4-dimethylphenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]azo]-3-hydroxy-1-naphthalenesulfonic acid (compound 3)

5

To a stirring solution of 1-diazo-2-naphthol-4-sulfonic acid (13.3 g, 53.1 mmol) and compound from Example 5f) (10.7 g, 53.1 mmol) in water (170 mL), sodium bicarbonate (13.38 g, 159.2 mmol) was added slowly. The resulting solution was heated at 60 °C with stirring overnight. The solution was cooled to room temperature, and was
10 adjusted to pH = 1 with 3 N hydrochloride solution. The purple precipitate was isolated by filtration and washed with water to provide the title compound as a red solid (23.3 g; 97%). MS(ES) m/z 451 [M-H].

While the preferred embodiments of the invention are illustrated by the above, it is
15 to be understood that the invention is not limited to the precise instructions herein disclosed and that the right to all modifications coming within the scope of the following claims is reserved.

What is claimed is:

1. A DNA construct encoding a cell-membrane receptor, whose transmembrane domain has been modified with a single point mutation to His.
5
2. A DNA construct encoding a cell-membrane receptor, whose transmembrane domain has been modified with point mutations to Thr and His.
3. A DNA construct of claim 2 where the Thr and His are three
10 residues apart.
4. A cell-membrane receptor encoded by a DNA construct of claims 1-3.
5. A genetically engineered cell containing and capable of
15 expressing a DNA construct of claims 1-3.
6. A cell of claim 5 containing a target gene under the expression control of a transcriptional control element responsive to the receptor of claim 4.
20
7. A method for activating a cell-membrane receptor which comprises exposing the cells of claim 5 with a metal-chelating receptor agonist.
8. A method of claim 7 wherein the cells are grown in a culture
25 medium and the exposing is effected by adding the metal-chelating receptor agonist to the culture medium.
9. A method of claim 7 wherein the cells are present in a host organism and the exposing is effected by administering the metal-chelating receptor
30 agonist to the host organism.
10. A method of claim 9 wherein the host organism is a mammal and the metal-chelating receptor agonist is administered in a therapeutically effective dose in a pharmaceutically acceptable carrier.
35
11. A method of claim 10 wherein the metal-chelating receptor agonist is administered orally.

12. A method of claim 10 wherein the metal-chelating receptor agonist is administered parenterally.
- 5 13. A kit which comprises at least one DNA construct of any of claims 1-3.
14. A kit of claim 13 which further comprises a metal-chelating receptor agonist.
- 10 15. A host organism containing a cell of claim 5.
16. A host organism of claim 15 which is of mammalian origin.
- 15 17. A mammal of claim 16 which is of human origin.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/50777

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 14/00; C12P 19/34
US CL : 530/350; 435/440

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 530/350; 435/440

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | KOLTCHINE, V. Agonist Gating and Isoflurane Potentiation in the Human gamma-Aminobutyric Acid Type A Receptor Determined by the Volume of a Second | 1, 4-6, 13 |
| --- | Transmembrane Domain Residue. Molecular Pharmacology. 1999, Vol. 56, pages 1087-1093, especially page 1087-1088, Material and Method section. | ----- |
| Y | SCHREIBER, S. Chemical Genetics Resulting from a Passion for Synthetic Organic Chemistry. Bioorganic and Medicinal Chemistry. 1998, Vol. 6, pages 1127-1152. | 2,3 |
| A | WIEDERRECHT, G. Characterization of High Molecular Weight FK-506 Binding Activities Reveals a Novel FK-506-binding Protein as Well as a Protein Complex. J. Biol. Chem. 25 October 1992, Vol. 267, No. 30, pages 21753-21760. | 1-17 |
| A | US 6,140,120 A (CRABTREE et al) 31 October 2000. | 1-17 |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "E" earlier application or patent published on or after the international filing date | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" document referring to an oral disclosure, use, exhibition or other means | "&" document member of the same patent family |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

02 May 2002 (02.05.2002)

Date of mailing of the international search report

Authorized officer

Dr. Celine Qian

Telephone No. 703-308-0196

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230